Metabolism, molecular hypometabolism and inflammation: Complications of proliferative physiology include metabolic acidosis, pulmonary hypertension, T reg cell deficiency, insulin resistance and neuronal injury
Dr. Shoemaker’s latest academic paper is published. This paper, though technical, reports the metabolic basis of conditions routinely found in CIRS. From metabolic acidosis to brain injury, and from T regulatory cell deficiency to pulmonary hypertension, these conditions are a direct effect of a change in energy production by a cell. Called proliferative physiology, if it is present, health is enormously affected for the worse. Certain exposures, particularly to actinomycetes and anti-fungals, make proliferative physiology much worse. Read the entire paper!
Featured Resources
COVID-19: What is compromised in immunocompromised? The overactive host response holds the danger
People with chronic illness and “immunocompromise” are warned to limit their exposures, even more than younger, immune uncompromised. We are better prepared to deal with COVID-19 when we know more about the immunometabolism of COVID-19 infection. So,...
Urinary Mycotoxins: A Review of Contaminated Buildings and Food in Search of a Biomarker Separating Sick Patients from Controls
This review looks at the extensive published materials, including a definition of mycotoxins; a case definition for illness acquired following exposure to WDB from 2008 US GAO, multiple biomarkers, proteomics, transcriptomics, volumetric CNS imaging studies...
The fulfillment of hope from GENIE continues.
Beginning with the storage of frozen PAXgene tubes in 2008, “for use when the science caught up to what we learned from CIRS,” followed by whole transcriptome sequencing that showed rich veins of new information, to the current targeted findings of GENI...
The 2018 SM diagnostic module paper is now published! Read it here!
This comprehensive paper is the culmination of extensive collaboration between SM certified providers Scott McMahon MD, Karen Johnson MD, Ming Dooley, Lysander Jim MD, Yvonne Berry MD and Ritchie Shoemaker MD; James Ryan PhD and Michael Schrantz, IEP.
New Paper- Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS
Evidence has accumulated since 2008 that intranasal, topical application of vasoactive intestinal polypeptide (VIP) can be administered safely to patients with a multi-system, multisymptom illness, called chronic inflammatory response syndrome (CIRS), acqui...